Article
Life-Threatening Inpatient Endocrine Emergencies
July 1, 2026
While Nashville’s honky-tonks and hot chicken stressed our endocrine systems, one talk at SHM Converge gave us the tools to master the metabolic chaos of true endocrine emergencies we may face in...
Article
Applying the 2024 ACG Guidelines on Acute Pancreatitis to Hospital Medicine
June 1, 2026
Acute pancreatitis is one of the most common gastrointestinal diseases managed by hospitalists. In the U.S., it accounts for nearly 300,000 admissions each year, more than one million inpatient days,...
Article
Urea Should Be Considered for Treatment of SIADH-Associated Hyponatremia
June 1, 2026
Clinical question: Is urea a safe and effective treatment option for syndrome of inappropriate antidiuretic hormone secretion (SIADH)-associated hyponatremia? Background: The management of...
Article
New Diabetes Medications and Holistic Management
November 3, 2025
Nearly one in four hospitalized 12patients in the U.S. has diabetes. These patients have almost twice the hospital readmission rate as those without diabetes, making it a critical area for...
Article
Should We Use Non-Insulin Diabetic Agents on Inpatients?
November 3, 2025
Since endocrinologists proved they could name studies equally as well as cardiologists with the RABBIT 2 and NICE SUGAR trials, guidelines have recommended the use of insulin for inpatients with...
Article
Parathyroidectomy Does Not Reduce Mortality or Morbidity in Mild Primary Hyperparathyroidism
December 1, 2022
Dr. Morvant Clinical question: Does parathyroidectomy improve mortality or morbidity in mild primary hyperparathyroidism? Background: It is known that in patients with severe hypercalcemia or...
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
